ArticleBiological procedures online2025
Uncovering Novel Susceptible Genes and Therapeutic Targets of Prostate Cancer: a Multi-omics Study Integrating Summary-based Mendelian Randomization Analysis and Molecular Docking.
Article in Biological procedures online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundUnderstanding the role of causal genes of prostate cancer (PrCa) can reveal key biological pathways and identify potential targets for treatment.
methodsWe investigated associations between genetically predicted gene expression levels and PrCa risk using cis-eQTL summary-based Mendelian randomization (SMR) and colocalization analysis. Findings were replicated using two independent PrCa GWAS. We then intersected the identified genes with differentially expressed genes (DEGs) identified from TCGA-PRAD dataset to obtain key genes. Furthermore, enrichment, protein-molecule network, immune infiltration, and epigenetic analyses were conducted to explore their biological pathways. Lastly, phenome-wide association study (PheWAS), drug prediction, and molecular docking simulation analysis were utilized to identify potential drugs.
resultsWe identified 15 genes in blood whose expression levels are putatively associated with PrCa, validated in at least one replication GWAS dataset. Using open-access mRNA-sequencing data, we found that ZNF217 and BNIP2 were key genes potentially important in PrCa pathogenesis. Single-cell RNA-sequencing analysis revealed that BNIP2 was predominantly expressed in a subset of endothelial cells, whereas ZNF217 was mainly enriched in epithelial cells. Downstream analysis revealed their involvement in epigenetic modulation-related pathways, while upstream analysis showed that upregulation of ZNF217 notably correlated with increased CpG methylation. Molecular docking simulation suggested doxorubicin, alsterpaullone, and camptothecin as potential drugs targeting these key genes.
conclusionsThese findings provide robust leads for understanding pathogenic mechanisms and developing therapeutic interventions for PrCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.